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ABSTRACT
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Introduction
Diabetes Mellitus is a metabolic disorder characterised by high sugar level over a prolonged period of time.
It is associated with the developing of complication due to a number of factors like the degree of
vulnerability, susceptibility, age, health status and immune system condition. (1) Patients with Diabetes
Mellitus along with morbidities receiving medications lead to different Drug related problems like
polypharmacy, drug-drug interaction, adverse drug reactions etc.

Objectives
To assess the Drug related problems in Type 2 Diabetes Mellitus patients with comorbidities using PCNE
classification and Hepler Strand classification in a tertiary care hospital in South India.

Methodology
A retrospective observational study conducted in Kasturba Hospital on patients with Type 2 Diabetes
Mellitus with at least one morbidity who were admitted in the year 2018 after ethical committee approval
and after relevant data were recorded in the CRF. Demographic data, medical and medication history,
laboratory values, drug utilisation pattern, drug related problem identified using different software and
classified using scales like PCNE classification and Hepler Strand classification were estimated and
recorded. Collected data were documented and analysed using descriptive statistics in Microsoft Excel.

Results
A total of 250 patients’ data diagnosed as Type 2 DM in the year 2018 was included in the study among
which majority 178(71.2%) patients were males and a greater number of 84(33.6%) patients were above 60
years old age. The mean age of the population was 62.5±12.86 years. Majority of the population had
93(37.2%) patients had hypertension as morbidity. It was found that 96(38.4%) patients received
monotherapy among which Human insulin as the maximum percentage of hypoglycemic. In this study a
total DRPs observed were 226. The average of 0.91 DRP was present in per patient. These are Potential
drug-drug interaction(7.09%), insufficient clinical information (37.6%), adverse drug reactions (4.86%), no
indication of drugs (0.44%), untreated indication(11.5%), prescribed drugs not available(1.77%), wrong
dose (1.32%), inappropriate drug form(0.44%), inappropriate dosing interval(0.88%), drugs prescribed but
not administered (3.53%), patient refused to take drugs(7.52%) and no update medication list (23%) were
the problems identified in this study.

Conclusion
This study concludes that identifying such problems is essential in preventing the occurrence of further
complications in the patients related to drugs. It shows that the clinical pharmacists play an important role in
the hospital to reduce the drug related problems in the patients.
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1. Introduction
Diabetes mellitus is a metabolic disorder characterised by high sugar level over a prolonged period.
Diabetes mellitus is associated with the developing of complication due to a number of factors like
the degree of vulnerability, susceptibility, age, health status and immune system condition (1).
Diabetes mellitus also to lead to different morbidities like Hypertension, Dyslipidemia, Chronic
kidney disease, Ischemic heart disease etc.
Globally 415 million adults are estimated to have diabetes currently and there are 318 million adults
with impaired glucose tolerance which put them at higher risk of developing disease in future (2).
According to World Health Organisation (WHO) estimation, the global prevalence of diabetes
among adults over 18 years old is 8.5% in 2014. There are 72.96 million cases of diabetes in adult
population in India. government survey showed 11.8% prevalence of Diabetes mellitus in India. (3)
There are people with type 2 Diabetes mellitus who can achieve normal blood sugar with lifestyle
modification such as diet, exercise etc. but a lot of them need oral hypoglycemics or insulin
therapy. The decision to prescribe medication depends upon different factors like blood sugar level
and morbidities

DRUG RELATED PROBLEMS
A Drug related problem is an event or circumstance involving drug therapy that actually or
potentially interferes with desired health outcomes. Drugs may not only have beneficial effects but
may also have adverse reactions. The most common drug related problems seen are Medication
errors, Adverse drug reaction, Adverse drug events, Drug-drug interactions, Prescription errors,
administration error associated with pharmacotherapy and are associated with increase in the cost of
the treatment.
A review literature conducted in Switzerland on Drug Related Problems in Hospital by KrahenbuhlMelcher A et.al comprised of analysis published in 1990-2005, showed that medication errors
occurred in a mean of 5.7% of all episodes of drug administration. Errors were detected throughout
the whole medication process where administration errors were accounted for more than half of all
the errors.(4)
The most important risk factors for adverse drug reactions are included as polypharmacy, female
sex, drug with narrow therapeutic range, use of anticoagulants or diuretics, renal elimination of
drugs and age more than 60 years old.
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SCALES USED FOR DETECTING DRUG RELATED PROBLEMS
1. PCNE CLASSIFICATION
PCNE or Pharmaceutical Care Network Europe classification is a scale used in the research to detect
the nature, prevalence and incidences of drug related problems and also in experimental studies of
Pharmaceutical Outcomes. It is also meant to use by the health care professionals to document Drug
related problems in Pharmaceutical process. The current version is V9.0 which was developed in a
workshop in February 2019.(5) The basic classification has 3 primary domains for problems, 9 primary
domains for Causes which are: 1) drug selection, 2) drug form, 3) dose selection, 4) treatment
duration, 5) dispensing, 6) drug use process,7) Patient related, 8)Patient transfer related, 9)
Others.

2. Hepler Strand classification
In the year 1990 LM Strand and her colleague published Drug Therapy problems in 8 categories.
The category includes:1. Drug use without indication 2. Improper drug selection 3. Sub therapeutic dose
4. Drug interaction 5. Overdose 6. Adverse drug reaction 7. Untreated indication 8. Failure to receive
drugs. According to that category the pharmacists generated a list of Drug therapy problems for each patient.
This resulted pharmacists to have a clear picture of patient’s drug therapy and medical condition
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Need for the Study
Type II Diabetes Mellitus is a costly illness and its related with significant mortality and morbidity (6).
They often have other comorbidities along with Diabetes and they receive complex medication regimen
which includes medications for dyslipidemia, hypertension, antiplatelet therapy and glycemic control (7).
These situations may lead to the increased risk of drug related problems. Patients may have concerns
when multiple regimens are started including prescribing errors, cost of medications and possible
adverse effects. Till date there are limited studies conducted in Type II Diabetes Mellitus with
comorbidities with respect to drug related problems.

In another study in 2013 by Hasniza Zaman Zuri et al. in a tertiary hospital in Malaysia, 200 patients with
a total of 387 Drug Related Problems were identified which include drug choice problems (23%), dosing
problems (16%) and drug interactions (16%) (8)
In another study conducted by Huri H Za and Ling LC Drug related problems in Type 2 diabetes mellitus
patients with dyslipidemia in a tertiary Hospital in Malaysia with 208 patients from January 2008 to
December 2011 where 406 DRPs were identified in 200 patients which include potential drug-drug
interaction (18.0%), drug not administered (14.3%), and insufficient awareness about health and disease
(11.8%). (9)
In Kasturba Hospital, Manipal which is a 2000 bedded tertiary care hospital, more than 2000 patients have
come with the complaints of Type 2 Diabetes Mellitus with other comorbidities in the period of last year.
There may be chances of getting drug related problems like potential drug-drug interactions, adverse drug
reactions, polypharmacy. To understand the pattern of these drug related problems, a study is required to
conduct..
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2.OBJECTIVES


To study the demographic of the patients.



To study the drug utilisation pattern in Type 2 Diabetes Mellitus patients



To study the Drug related problems in Type 2 Diabetes Mellitus patients with comorbidities
using PCNE classification and Hepler Strand classification

8
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3. METHODOLOGY
3.1 Study Site: Kasturba Hospital, Manipal.

3.2 Study Design: Retrospective Observational Study

3.3. Study Period: August 2019 to March 2020

3.4 Ethical Clearance: Obtained from the Institutional Ethics Committee, Kasturba Hospital, Manipal
MAHE. (Appendix 1) (560-2019)

3.5 Sample Size: A total number of 250 patients diagnosed with Type 2 Diabetes Mellitus with at least
one comorbidity who are admitted in the year 2018 were included in the study.
Sample size is calculated using following formulae:

n=

𝑧2
𝛼 ⋅𝑝𝑞
2
𝑑2

𝑧𝛼
2

=1.96 at 5% level of significance.
p=0.8 proportion in population having the
characteristic of interest.

(1.96)2 ⋅0.8⋅0.2
(0.05)2

=246

q=1-p, 1-0.8=0.2, d=0.05 precision

Therefore, the minimum the sample size required is 246.
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3.6 Study Criteria:
Inclusion Criteria:


Age above 30 years old



Patient diagnosed with type 2 Diabetes Mellitus with at least one antidiabetic agent



Type 2 Diabetes mellitus with its comorbidities and prescribed with at least one regimen



Patients with Polypharmacy (drugs>5)
Exclusion Criteria:



Gestational diabetic patients



Diabetes with Psychiatric problems.



Type 1 Diabetes Mellitus patients.

3.7 Sources of data collection:
Patients Case Records which contained the following data:


Patient demographics, Patient history notes, Laboratory test, Nurses’ drug administration
record, Drug treatment chart, Outcomes, Discharge medication and follow ups

3.8 Documents Used: Case Record Form (CRF) Appendix 2
3.9 Resources used to identify DRPS: Micromedex, Medscape, Lexicomp, Drugs.com etc.
3.10 Scales used to classify the DRPS: Hepler Strand Classification and PCNE Classification.
Appendix 3 and Appendix 4 respectively
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3.11 Operation Modality:
More than 6000 patients were admitted with the final diagnosis of Diabetes Mellitus Type II with
comorbidities. Using randomized table in Microsoft Excel, 300 files were selected. Using inclusion and
exclusion criteria data, the medical records of 250 patients were obtained from the Medical Record
Department (MRD). The data from the patients’ file were reviewed and documented in the CRF individually
for each patient. The Drug related problems like medication error, drug-drug interactions, error in
administration, adverse events, error in dosage etc. were identified using Softwares like Micromedex,
Drug.com, Medscape, Lexicomp and then classified using scales like PCNE Classification and Hepler
Strand Scale and the data obtained are entered using Excel spreadsheet and the analysis of the data is done.

Designing of the data collection form

Validation of the study design form

Data collection by PI and Co-PI from the MRD as per inclusion and exclusion criteria using a
Case Record Form (CRF)

Identification of DRPs like drug-drug interactions,
adverse effects, Medication errors etc. using different
resources

Classify the identified DRPs using PCNE classification
Scale and Hepler Strand Scale.

Data entered into Microsoft Excel Spreadsheet

Analysis of the data

12
Outcome assessed

3.12 COLLECTION OF DATA
As per criteria the medical records of randomly selected Type 2 DM patients with comorbidities
patient who were admitted in the year 2018 were reviewed and the details of the patient were
entered in a case record form. Demographic details like age, sex, number of hospital days stay,
family history, social history (smoker or alcoholic), age of onset of Diabetes mellitus were noted.
Information regarding the presence of any risk factors or chronic illness, medical history,
medication history for Diabetes mellitus and other morbidities (if present in the history) and type
of admission were retrieved from the files in a structured CRF. Other important information like
Drug utilisation pattern (Like monotherapy, dual therapy, or triple therapy) along with any
problems like drug adverse reaction, drug-drug interactions if reported during the stay in hospital
were retrieved and noted in a structured CRF. The various laboratory values were noted down and
are classified and diagnosed according to normal glucose level and normal HbA1C level which
discriminates the normal from the diabetic patients.

3.13 Data analysis
The data obtained from the Medical Record Department of the patients were analysed and then entered
in Microsoft Excel spreadsheet. Following data were analysed:
1. Demography of the patients
2. Past medical history
3. Allergic history
4. Laboratory investigation report
5. Number of drugs prescribed
6. Drug utilisation pattern
7. Drug related problems identified using PCNE classification and Hepler Strand classification
3.14 Statistics applied:
The frequency of the patients, the mean and the standard deviation were calculated using descriptive
analysis. All the data of the patients were presented in Percentages.
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4.RESULTS
A total number 250 patient’s data were collected who were diagnosed with Diabetes Mellitus type 2 along
with comorbidities as per inclusion criteria.
1)Demographic Status of the patients with Type 2 Diabetes Mellitus
a) Gender wise distribution:
Out of 250 type 2 DM patients, 178(71.2%) patients are males and 72 (28.8%) are females which is shown
in Table 1.
Table No. 1: - Gender wise distribution
Sl. No.

Gender

No. of patients (%)
(n=250)

1.

Male

178(71.2)

2.

Female

72(28.8)

b) Age wise distribution:
Among 250 type 2 DM patients, 31(12.4%)patients were in the age group of 30-40years, 52(20.8%) were in
the age group of 41-50years and 83(33.2%) were in the age group of 51-60years and 84(33.6%) were in the
age group of above 60 years old. Mean age of the study population is 63.5±13.41years. This is shown in the
Table no.2 below
Table No 2: - Age wise distribution
Sl. no.

Age in groups (in

Number of patients (%)

years)

N= 250

1.

30-40

31(12.4%)

2.

41-50

52(20.8%)

3.

51-60

83(33.2%)

4.

>61

84(33.6%)

Mean±SD

62.5±12.86
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c) Duration of Diabetes Mellitus:
Out of 250 type 2 DM patients, 74(29.6%) were recently diagnosed, 76 (30.4%) were diagnosed in past 1-5
years, 41(16.4%) were diagnosed in the past 6-10 years, 3 (1.2%) were diagnosed in the past 11-15 years, 4
(1.6%) were diagnosed in the past 15-20 years and 52 (20.8%) history of diagnosis was not mentioned as
shown in the Figure below :

DURATION OF T2DM
PATIENT PERCENTAGE %

35
30
25
20
15

29.6

30.4

10

20.8

16.4

5
1.6
1.2
Past 6-10 Past 11-15 Past 15-20
Not
years
years
years
mentioned

0
Recently
diagnosed

Past 1-5
years

DURATION OF DM

Figure No.1: Duration of Diabetes Mellitus type 2

d) Length of hospital stay wise distribution:
Out of 250 type 2 DM patients, 151(60.4%) patients stayed for 1-5 days, 82(32.8%) patients stayed for 6-10
days, 14(5.6%) patients stayed for 11-15 days and 3(1.2%) patients stayed for 16-20 days as shown in the
Table below:
Table No. 3: - Length of Hospital days
Sl no.

No. of hospital days

No. of patients (%)
N=250

1.

1-5

151(60.4)

2.

6-10

82(32.8)

3.

11-15

14(5.6)

4.

16-20

3(1.2)
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e) Comorbidities wise distribution:
Out of 250 type 2 DM patients, 93(37.2%) patients have Hypertension, 25(10%) patients have Dyslipidemia,
14(5.6%) patients have Ischemic heart disease, 10(4%) patients have Bronchial Asthma, 14(5.6%) patients
have Chronic Kidney disease, 23(9.2%) patients have Renal calculi and 71(28.4%) patients have other
comorbidities along with Diabetes Mellitus Type 2 shown in the figure below

patient paercentage %

comorbidities
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

comorbodites

Figure No.2: - Comorbidities wise distribution
f) Social history status of DM patients
For alcoholics: Out of 250 type 2 DM patients, 42(16.8%) patients are alcoholics, 131(52.4%) patients are
non-alcoholics and 11(4.4%) patients are reformed alcoholics and for the rest it was not mentioned.
For smoker: Out of 250 type 2 DM patients, 20(8%) patients are smokers, 157 (62.8%) patients are nonsmokers and 8 (3.2%) patients are reformed smokers and for the rest it was not mentioned.

Aloholics

Smokers
8%

16.80%

26%

26.40%

4.40%

3%
52.40%

Yes

No

Reformed

63%

Not mentioned

Figure No.: 3:- No. of Alcoholics

Yes

No

Reformed

Not mentioned

Figure No 4: - No. of Smokers
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g) Body Mass Index of DM patients
Out of 250 type 2 DM patients, 99(39.6%) patients have normal BMI, 77(30.8%) patients are overweight,
22(8.8%) patients are in the category of obesity, 4(1.6%) patients are under category of Morbid obesity and
48(19.2%) patients were unable to stand as shown in the Table below.
Table No 4.: - Body Mass Index of DM patients
Sl. No.

BMI (Body Mass Index)

No of patients (%)
N=250

1

Normal (18.5-24.9)

99(39.6)

2

Overweight (25-29.9)

77(30.8)

3

Obesity (30-34.9)

22(8.8)

4

Morbid obesity (35-39.9)

4(1.6)

5

Unable to stand

48(19.2)

h) HbA1C wise distribution:
Out of 250 type 2 DM patients, 13(5.2%) patients have HbA1C less than 5.9%, 25(10%) patients have
HbA1C 6.0-6.5%, 38(15.2%) patients have HbA1C 6.6-7.0%, 141 (56.4%) patients have HbA1C more than
7.1% and for 33 (13.2%) patients HbA1C was not mentioned as shown in the figure below:

HbA1C

patient percentage %

60
50
40
30
20
10
0
less than 5.9%

6.0-6.5%

6.6-7.0%

more than7.1 not mentioned

HbA1c level

Figure No. 5: - HbA1c wise distribution
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i)Diabetic complication wise distribution:
Out of 250 type 2 DM patients 9 (3.6%) patients had Diabetic Retinopathy, 6 (2.4%) patients had Diabetic
Nephropathy, 7 (2.8%) patients had Diabetic Neuropathy, 6 (2.4%) had Diabetic Foot Ulcers, 1 (0.4%) had
Diabetic Nephropathy and Diabetic Foot Ulcers, 1(0.4%) patients had Diabetic Neuropathy and Diabetic
Foot Ulcer, 1(0.4%) patients had Diabetic Neuropathy and Nephropathy, 3 (1.2%) patients had Diabetic
Retinopathy and Nephropathy, 1(0.4%) patients had Diabetic Retinopathy, Neuropathy and Nephropathy, 1
(0.4%) patients had all the complications of Diabetic Neuropathy, Nephropathy, Foot ulcer and Retinopathy
and 214( 85.6%) showed no complications as shown in the Table below:
Table No.5: Diabetic Complication
Sl. No.

Complications

No. of patients (%)
N=250

1.

Diabetic retinopathy

9 (3.6%)

2.

Diabetic nephropathy

6 (2.4%)

3.

Diabetic neuropathy

7 (2.8%)

4.

Diabetic foot ulcer

6 (2.4%)

5.

Nephropathy +diabetic foot

1 (0.4%)

ulcer
6

Neuropathy+ diabetic foot

1(0.4%)

ulcer
7

Neuropathy+ nephropathy

1(0.4%)

8

Retinopathy +nephropathy

3 (1.2%)

9

Retinopathy+ neuropathy+

1(0.4%)

nephropathy
10

Retinopathy+ neuropathy+

1 (0.4%)

nephropathy+ diabetic foot
ulcer
11

None

214 (85.6%)
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2) Drug Utilisation Pattern in patients with Type 2 Diabetes Mellitus

j) No. of drugs prescribed for Diabetes Mellitus Type II:
Out of 250 type 2 DM patients, 96 (38.4%) patients received Monotherapy, 87(34.8%) patients received
Dual therapy, 42(16.8%) patients received Triple therapy, 13(5.2%) patients received Quadruple therapy
during the stay in the Hospital. This has been shown in the Figure below:
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Figure No. 6: Number of drugs prescribed for T2DM
k) Type of Diabetic medications:
Out of 250 type 2 DM patients, 97(38.8%) patients received only oral hypoglycemics, 48(16%) patients
received only Insulin, 95(38%) received both oral hypoglycemics and Insulin. This has been shown in the
Table below:
Table No.6: Type of Diabetic Medications:
Sl. No.

Type of Diabetic

No. of patients (%)

Medications

N=250

1

Only oral

97(38.8)

2

Only Insulin

48(16)

3

Oral hypoglycemics

95(38)

+ Insulin
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l) Classes of Hypoglycemics prescribed to the patients:
Out of 250 type 2 DM patients, 238(95.2%) patients received therapy for Diabetes and the remaining
12(4.8%) did not receive any therapy during the stay in the Hospital.
i)Out of 250 DM patients, 96(38.4%) patients received Monotherapy. This has been shown in the Figure
below:
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Figure No.7: Monotherapy wise distribution

ii)Out of 250 DM patients, 87(34.8%) patients received Dual Therapy. This has been shown in the Figure
below:
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Figure No. 8: Dual Therapy wise distribution
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iii)Out of 250 DM patients 42(16.8%) patients received Triple Therapy. This has been

shown in the Figure

below:
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Figure No.9 Triple Therapy wise distribution
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iv)Out of 250 DM patients, 13(5.2%) patients received Quadruple Therapy. This has been shown in the
Figure below:
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Figure No.10: Quadruple therapy wise distribution

3)Drug Related Problems in patients with Type 2 Diabetes Mellitus

i) HEPLER STRAND CLASSIFICATION:
Total DRPs observed were 226. The average of 0.91 DRP was present in per patient. Out of 250
DM patients, 95(38%) patients showed at least Drug related problems .Out of them, 1(0.4%) patients
showed problems like Drug without indications, 3(1.2%) patients showed problem like Improper
drug selection, 20(8%) showed problem like Drug-drug interaction, 2(0.8%) showed problem like
Overdose, 11 (4.4%) showed problem like Adverse drug reaction, 15(6%) patients showed problem
like Untreated indication, 5(2%) patients showed problem like Failure to receive drugs and
56(22.4%) showed Other problems.
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HEPLER STRAND CLASSIFICATION
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Figure No. 11: Hepler Strand Classification
ii) PCNE CLASSIFICATION:

PCNE classification scale is used to identify the problems in the patients with T2DM along with
comorbidities. The problem identified using the above scale are :1) Inappropriate drugs prescribed to the
patients,2) no indication of drugs, 3) Inappropriate combination of drugs, 4) No or incomplete drug
treatment inspite of existing indications 5) Inappropriate drug form for a particular patient 6) Drug dose too
high 7) Prescribed drug not available 8) Inappropriate timing of administration of drugs 9) Drug not
administered at all 10) Patient took no/less drugs during the stay in the hospital 11) No updated medication
list was available 12) Insufficient clinical information about the patients.
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C1.2: Inappropriate drug (within guidelines but otherwise contraindicated)
Out of 250 patients,11(4.86%) patients had received inappropriate drugs which are contraindicated to them.
These drugs caused adverse reaction were complained by the patients during the stay in the hospital. The
details are shown in the table below:
Table no: 7: Inappropriate drugs (within guidelines but otherwise contraindicated)
Sl. No.

Summary of problems

Frequency (%)

1.

Case of hypoglycemia on due to
Inj.Actrapid.
Patient complaint of generalised
itching due to Ceftriaxone
administration which is an adverse
effect of Ceftriaxone.
Patient complaints of drowsiness
because of T. Lorazepam.
Patient complaints of drowsiness
because of T. Quetiapine
Patient complaints of formation of
hives on all over the body which is due
to administration of T.Atrax
(antihistamine)which is the adverse
effect of the same drug
The patient complaints of drowsiness
because of T.Vozet
The patient complaints of vomiting and
watery stools on administration of
Enaxoparin which are the adverse
effect of the same drug.

1 (0.44)

The patient developed allergic reaction
on all over the body during the stay in
hospital due to administration of tablet
azithromycin.

1(0.44)

The patient developed rashes after the
administration of Enoxaparin which is
a frequently seen adverse effect of the
drug.

1(0.44)

2

3
4
5

6
7.

8.

9.

10.

2 (0.88)

1(0.44)
1(0.44)
1(0.44)

1(0.44)
1(0.44)

The patient complaint of hypoglycemia 1(0.44)
due to administration of Insulin
Glargine
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C1.3: No indication of drugs
Out of 250 type 2 DM patients, 1(0.44) patients had received drugs without any indication. This has
been shown in the table below:
Table No.8: No indication of drugs
Sl. No.

Summary of the problem

Frequency (%)

1.

Aspirin and atorvastatin were given
without any indicate during the stay in the
hospital

1(0.44)

C 1.4: Inappropriate combination of drugs, or drugs and herbal medication, or drugs and
dietary supplements.
Out of 250 type 2 DM patients, 16(7.09%) patients received inappropriate combination of drugs
which can cause adverse effects. This has been shown in the table below:
Table No.9: Inappropriate combination of drugs, or drugs and herbal medication, or drugs and dietary
supplements
Sl. No.

Summary of the problems

Frequency (%)

1.

a) Alprazolam+ Dexamethasone
causes increased risk of respiratory
and CNS depression.
b) Dexamethasone+Tramadol
increases the tramadol exposure.

1(0.44)

2.

Aspirin+ metformin induced
hypoglycemia on 25/10.

1(0.44)

3.

Concurrent administration of
aspirin and furosemide has
possible nephrotoxicity
Concurrent administration of
Atropine sulphate /diphenoxylate
HCl and Potassium Chloride is
contraindicated and may have high
risk of GI lesions.
Concurrent administration of
insulin and ofloxacin has increased
risk of
hypoglycemia/hyperglycemia.
Ciprofloxacin + Glimepiride can
cause increased risk of
hypoglycemia or hyperglycemia

1(0.44)

4.

5.

6.

1(0.44)

1(0.44)

1(0.44)

7.

8.

9.

10.
11.

12.

13.

14.

15.

Ciprofloxacin + sitagliptin can
cause increased risk of
hyperglycemia or hypoglycemia
Ciprofloxacin + Metformin can
cause increased risk of
hyperglycemia or hypoglycemia
Concurrent use of Tramadol and
phenytoin causes reduced
Tramadol exposure.
Domperidone + ticagrelor can
cause QT prolongation
Gabapentin and methadone
concurrent use can cause
respiratory depression.
Metolazone + furosemide
(increases the risk of fluid and
electrolyte imbalance), metoprolol
+ clonidine(increased risk of sinus
bradycardia)
Ramipril and Spironolactone use
can cause increased risk of
hyperkalemia
The concurrent use of Gabapentin
and Tramadol can cause
respiratory depression.
Tramadol+Clarithromycin(increase
clarithromycin concentration and
cause respiratory depression.

1(0.44)

2(0.88)

1(0.44)

1(0.44)
1(0.44)

1(0.44)

1(0.44)

1(0.44)

1(0.44)

C1.6: No or incomplete drug treatment in spite of existing indication.
Out of 250 type 2 DM patients, 26(11.5%) patients did not receive any medications in spite of existence of
indications. This has been shown in the table below:
Table No.10: No or incomplete drug treatment in spite of existing indication
Sl. No.

Summary of the problems

No. of patients (%)
N=250

1.

Hypoglycemics were not
given at all even though
the sugar levels were
high. Sugar levels were
not monitored properly.

12(5.307))

2.

The patient had high

4(1.76)

cholesterol levels (TG323) but the patient was
not prescribed with any
lipid lowering agents.
3.

No drugs for acute kidney

1(0.44)

injury
4.

Patient complained of

2(0.88)

cough throughout the stay
but o medication was
prescribed.
5.

The patient had insomniac

2(0.88)

problem but no
medication was prescribed
6.

More oral hypoglycemics

1(0.44)

/Insulin should have been
given since the glucose
level was persistently
high.
7.

No drug has been given

1(0.44)

for Hypothyroidism.
8.

No drug has been

2(0.88)

prescribed for Urinary
tract infection.
9.

No antihistamine was

1(0.44)

given for the body rashes
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C2.1: Inappropriate drug form (for this patient):
Out of 250 type 2 DM patients, 1(0.44%) patients received inappropriate from of drugs. This has
been shown in the table below:
Table No.11: Inappropriate drug form (for this patient)
Sl. No.

Summary of the

Frequency(%)

problems
1.

The patient is not able

1(0.44)

to swallow food since
10 days but he was
given drugs in tablet
form.

C5.1: Prescribed drug not available
Out of 250 type 2 DM patients, for 4(1.77%) patients prescribed drugs were not available. This has
been shown below:
Table No.12: Prescribed drug not available
Sl. No.

Summary of the problem

Frequency(%)

1.

T.Pioz was not given on 07/08/2018

1(0.44)

because it was unavailable in the
pharmacy.
2.

Oint.candid was not available

1(0.44)

3.

Prescribed drug (Minoxidil and

1(0.44)

Ebernet cream) were not available on
05/06 and 07/06 respectively
4.

Prescribed drugs (Minoxidil and

1(0.44)

Ebernet cream) were not available on
05/06 and 07/06 respectively.
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C 5.3: Wrong drug, strength or dosage advised (OTC)
Out of 250 type 2 DM patients, 3(1.32%) patients received drugs of wrong strength. This has been
shown in the table below:
Table No.13: Wrong drug, strength or dosage advised (OTC):

Sl. No.

Summary of the

Frequency(%)

problem
1.

T. Thyronorm dose

1(0.44)

strength was
mentioned as 75 mg,
which is incorrect
2.

Dose of T.Thyronorm 1(0.44)
is mentioned as 50
mg where as it is
supposed to be
50mcg

3.

The maximum dose

1(0.44)

available for
fexofenadine is 180
mg but it was
mentioned as 2gm.
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C6.1: Inappropriate timing of administration or dosing interval:
Out of 250 type 2 DM patients,2(0.88%) patients received drugs at inappropriate time or at
inappropriate interval of time. This has been shown in the table below:
Table No.14 : Inappropriate timing of administration or dosing interval
SL. No.

Summary of the problem

Frequency(%)

1.

T.Amlodipine on 6/12/18

1(0.44)

was given at night, whereas
on 08/12/18 it was given in
the morning.
2.

Yes. Amlodipine was not

1(0.44)

given on 5/12 and on 6/12
the morning dose was given
in the night and on 7/12 the
morning dose was not given.
C6.4: Drug not administered at all
Out of 250 type 2 DM patients, for 8(3.53%) patients no drug was not administered at all during the
stay in the hospital. These drugs were prescribed but the patient did not receive during the stay in the
hospital. This has been shown in the table below:
Table No.15: Drug not administered at all
Sl. No.

Summary of the problem

Frequency(%)

1.

T.Amlodipine dose

1(0.44)

missed on 5/12/18 and
7/12/18.
2.

Insulin was not

7(3.08)

administered though the
Fasting Blood Sugar was
higher than the normal
level.
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C7.1: Patient uses/takes less drug than prescribed or does not take the drug at all
Out of 250 type 2 DM patients, 17(7.52%) patients refused to take drugs during the stay in the
hospital. This has been shown in the table below:
Table No.16: Patient uses/takes less drug than prescribed or does not take the drug at all
Sl. No.

Summary of the problem

No. of patients (%)
N=250

1.

Patient refused to take oral

4(1.76)

hypoglycemics
2.

Lack of patient compliance 2(0.88)
with hypoglycemic

3.

Patient refused take the

1(0.44)

oral medications of other
morbidities.
4.

Patient refused to take

1(0.44)

syp.keylite and insulin
doses were skipped(on
06/05)
5.

patient refused to take

1(0.44)

T.Zolfresh.
6.

Patient refused to take T.

1(0.44)

K bind.
7.

Patient refused to take

6(2.65)

insulin during the
discharge. So patient was
prescribed with oral
hypoglycemics.
8.

The patient did not wake

1(0.44)

up and did not take the
medication.
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C8.2: No updated medication list available
Out of 250 type 2 DM patients, for 52(23%) patients the history of hypoglycemics were not recorded
during the admission in the Hospital. This has been shown in the table below:
Table No.17: No updated medication list available
Sl. No.

Summary of the problem

Frequency(%)

1.

The history of

52(23)

hypoglycemics were not
recorded.

C8.4: Insufficient clinical information about the patient:
Out of 250 type 2 DM patients, 85(37.6%) patients had insufficient clinical information during the
stay in Hospital. this has been shown below in the table below:
Table No. 18: Insufficient clinical information about the patient
Sl. No.

Summary of the problem

Frequency(%)

1.

No history of diabetes was recorded.

52 (23)

2.

Though the patient is a diabetic and dyslipidemic

33(14.6)

patient the sugar level and lipid levels were not
checked
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DISCUSSION
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5. Discussion
This study was conducted in a Tertiary care hospital in South India was a retrospective observational study.
The aim of the study was to find the drug utilisation pattern and DRPs (Drug Related Problems) in the
patients diagnosed with Type 2 diabetes mellitus with comorbidities admitted in the Hospital in the year
2018. In the present study, 250 patients who met the inclusion criteria were included and their medication
order, nurses’ records and the discharge summary were reviewed and noted down in the Case Record Form
(CRF).
The present study shows that among 250 T2DM patients 178(71.2%) patients are males and 72 (28.8%) are
females. This could be because a greater number of male patients got admitted in the hospital setting
compared to females. A similar study was done by Huri HZ(8) in a tertiary care hospital of Malaysia where
it showed that 52% male were admitted which is comparatively more than the female admission who met
with the inclusion criteria. In another study conducted with 47,532 patients in a hospital in Colombia by
Mendoza et al (10) it was observed that 56.3% patients were females which is different from the above
studies.
It was also observed that among the 250 T2DM patients , 31(12.4%)patients were in the age group of 3040years, 52(20.8%) were in the age group of 41-50years and 83(33.2%) were in the age group of 51-60years
and 84(33.6%) were in the age group of above 60 years old. Mean age of the study population is
62.5±12.86years This implies that the number of elderly population admission was more than the nonelderly population. In a similar study conducted by Ayele Y et al(2) in a tertiary care hospital in Ethiopia,
their finding was slightly different with our study, their study showed that most of the admission was non
elderly population. In another study conducted in a tertiary teaching hospital of Karnataka in the year 2017
by Acharya eta al(11) which showed that among 116 DM patients with complications 12(10.3%) patients
were below 40 years old, 66(55.9%) patients were between 41-60 years old and 38(32.8%) were above 60
years old. Whereas DM patients with complications 6(5.2%) were below 40 years old, 66(56.9%) patients
were aged between 41-60 years old and 44(37.9%) were above 60 years old. In both the cases a greater
population lied between the age group 41-60 years old. Another study by Poonam et al(12) conducted in
Gorakhpur, India 61% of patients aged between 40 – 60 years old.
We found that among 250 DM patients, 74(29.6%) were recently diagnosed, 76 (30.4%) were diagnosed in
past 1-5 years, 41(16.4%) were diagnosed in the past 6-10 years, 3 (1.2%) were diagnosed in the past 11-15
years, 4 (1.6%) were diagnosed in the past 15-20 years and 52 (20.8%) history of diagnosis was not
mentioned. This implies that more number people were diagnosed in the past 1-5 years compared to others.
In a similar study conducted by Ayele Y et al (2) in a teaching hospital in Ethiopia and they found in their
study was slightly different compared to ours where more than half of the population with diabetes was
more than 5 years.
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It was then observed that 151(60.4%) patients stayed for 1-5 days, 82(32.8%) patients stayed for 6-10 days,
14(5.6%) patients stayed for 11-15 days and 3(1.2%) patients stayed for 16-20 days. In a similar study
conducted by Huri Zet al(8) in a tertiary care hospital in Malaysia which showed similar type of result as
ours where it was observed that number of patients stayed for less than 7days is 143 (71.5%), 8 to 14 days is
38 (19.0%) and for more than 15 days is 19 (9.5%). Another similar study conducted in a tertiary teaching
hospital to assess the Quality of life among the diabetic patients by Prajapati VB et al(13) observed that
155(6.2%) patients were hospitalised for less than 10 days, 67(26.8%) patients stayed for 10-20 days and
22(8.8%) patients stayed for more than 20 days in the hospital. Both the study showed that the highest
percentage of patients stayed for less than 10 days in the hospital.
It was found that ,among 250 DM patients 93(37.2%) patients had Hypertension, 25(10%) patients had
Dyslipidemia, 14(5.6%) patients had Ischemic heart disease, 10(4%) patients had Bronchial Asthma,
14(5.6%) patients have Chronic Kidney disease, 23(9.2%) patients have Renal calculi and 71(28.4%)
patients had other comorbidities. In a similar type of study conducted by Nandukkandiyil N et al (6) in a
tertiary care hospital of Qatar showed that 67(72.8%)patients had Hypertension, 6(6.5%) patients had
Ischemic heart disease,40 (43.5%) patients had dyslipidemia,4(4.3%) patients had Chronic kidney diseases.
Both the study showed that most of the DM patients had hypertension as comorbidity who were admitted. In
a similar study conducted in a hospital of UAE by Maskari et al(14) showed that 178(34.9%)DM patients had
hypertension, 152(34.4%) patients had dyslipidemia, 279(61.2%) patients had renal complications and
73(14.4%) patients had cardiovascular diseases.
Out of 250type 2 DM patients, 42(16.8%) patients were alcoholics, 131(52.4%) patients were non-alcoholics
and 11(4.4%) patients were reformed alcoholics and for remaining 66(26.4%) patients were not mentioned. I
was then observed that 20(8%) patients are smokers, 157 (62.8%) patients are non-smokers and 8 (3.2%)
patients are reformed smokers and for remaining 65(26%) patients were not mentioned. According to a
similar study conducted by Babu M(15) et al in a teaching care hospital of India showed similar kind of a
result that 72 (70.5%) were non-smokers, 30(29.4%) were smokers, 84(82.3%) were non alcoholics and
18(17.6%) were alcoholics.
It was then observed that among 250 type 2 DM patients, 13(5.2%) patients have HbA1C less than 5.9%,
25(10%) patients have HbA1C 6.0-6.5%, 38(15.2%) patients have HbA1C 6.6-7.0%, 141 (56.4%) patients
have HbA1C more than 7.1% and for remaining 33(13.2%)patients were not recorded. This implies that a
greater number of patients had HbA1C more than 7.1%. a similar study conducted by Huri HZ et al(9) in a
tertiary hospital in Malaysia it was found that 159(74%) DM patients had HbA1C more than 6.5% and only
49(26%) patients had A1C less than 6.5%.In another study conducted by Alba et al(16) in Colombia it was
found that a large proportion of patients had HbA1C more than 7.0%.
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We also observed that out of 250 type 2 DM patients 9 (3.6%) patients had Retinopathy, 6 (2.4%) patients
had Nephropathy, 7 (2.8%) patients had Neuropathy, 6 (2.4%) had Diabetic Foot Ulcers, 1 (0.4%) had
Nephropathy and Foot Ulcers, 1(0.4%) patients had Neuropathy and Foot Ulcer, 1(0.4%) patients had
Neuropathy and Nephropathy, 3 (1.2%) patients had Retinopathy and Nephropathy, 1(0.4%)
patients had Retinopathy, Neuropathy and Nephropathy, 1 (0.4%) patients had all the DM complications of
Neuropathy, Nephropathy, Foot ulcer and Retinopathy and 214( 85.6%) showed no complications.
In a study conducted by Sosale A et al(17) in a tertiary hospital in India showed that 13.15% DM patients
had Neuropathy, 6.1% had Retinopathy, 1.06% had Nephropathy and others showed macrovascular
complications.
Then we observed the drug utilisation pattern among the patients during the stay and during the discharge of
the patients. Among the 250DM patients, 96 (38.4%) patients received Monotherapy, 87(34.8%) patients
received Dual therapy, 42(16.8%) patients received Triple therapy,13(5.2%) patients received Quadruple
therapy during the stay in the Hospital. this implies that a greater number of patients received Dual
Therapy. In a similar study conducted by Babu M et al(15) in a tertiary care teaching hospital of India showed
that 37.3% of patients received single antidiabetic agents, 37.3% patients received two antidiabetic agents,
17.6% of patients received three antidiabetic agents and 1% of patients received four anti diabetic agents
Another similar study conducted for 3 consecutive years in a tertiary teaching hospital in Karnataka, India to
assess the prescription pattern of hypoglycemics by Acharya et al(18) it was observed that 331(42.8%) in
2008, 258(36.9%) in 2009 and 267(41.3%) in 2010 were given as monotherapy. 265(34.3%) in 2008,
271(38.8%) in 2009 and 210(32.5%) in 2010 were given as dual therapy. 121(15.7%) in 2008, 105(15%) in
2009 and 95(14.7%) in 2010 were given as triple therapy. A very less percentage of people like 28(3.6%) in
2008, 21(3%) in 2009 and 12(1.9%) in 2010 were given as quadruple therapy. Thus, it implies that the
highest percentage of monotherapy was given to patients during the stay in the hospital.
It was found that Human insulin (50%) was prescribed among the maximum percentage of monotherapy.
Metformin and Glimepiride(21.89% ) was prescribed as maximin percentage of dual therapy, Glimepiride+
Insulin + Metformin(35.71%) was prescribed among maximum percentage of triple therapy, and
Metformin+ Glimepiride+ Acarbose+ Insulin , Metformin+ Glimepiride+ Insulin+ others and Sitagliptin+
Insulin + combination of glimepiride and metformin(15.38%)was prescribed among maximum percentage
of quadruple therapy. In a similar study conducted by Sharma JK eta al(19) in a hospital in India showed
slightly different result than ours. The most commonly used antidiabetic as monotherapy was Metformin.
Metformin (89.27%), Glimepiride (29.11%) and Insulin (15.28%) were commonly prescribed anti diabetic
drugs. Biguanide + sulfonylurea was the most common two drug combination. In another study conducted
by Acharya et al(18) in a tertiary care hospital in Karnataka, India showed that most common monotherapy
given to the patients was Insulin which similar to our study.
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In the present study 226 DRPs were found and the average was found to be 0.91 DRP per patient. The drug
related problems were classified according to PCNE classification and Hepler Strand classification. The
most common DRP found was insufficient clinical information about the patients was 85(37.6%).
The other Drug related problems in the DM patients detected 11(4.86%) of inappropriate drugs prescribed
which caused adverse reactions. 4 allergic side effect were reported and 7 non allergic side effects were
complained by the patients during the stay in the hospital. In a similar study conducted by Huri HZ et al(9) in
a teaching hospital in Malaysia showed a similar result. They observed 31 adverse effects among which 4
were reported as allergic reaction and 27 were non allergic adverse reactions.
It was the observed that in DM patients out of 226 DRPs 1(0.44%) DRP was observed as patients receiving
drugs without any indication. They did not show any symptoms but still received the drugs. In a study
conducted by Zazuli Z et al(7) in a tertiary care hospital of Indonesia showed that 24 (9.2%)DM patients
received drugs though they showed no clear indication for the drugs. The result showed in our study was
comparatively low than the result showed in the study.
The next DRP observed that DM patients received inappropriate combination of drugs and showed potential
drug-drug interaction when identified using different drug interaction checker. The number of this DRP
observed was 16(7.09%). Metformin and Ciprofloxacin 2(0.88%) were most common drug-drug interaction
found. In a study conducted by Dinesh KU et al(20) in a tertiary care teaching hospital in Nepal showed that
among 182 patients receiving a total of 685 medications showed 43(23.6%) of potential drug drug
interaction among the DM patients. The most common potential drug-drug interaction was found to be
between Metformin and Enalapril. In another study conducted by Hussein RN et al(21) in a tertiary care
hospital in UAE showed among 278 patients 719(40.8%) drug-drug interactions were found. This is
probably due to polypharmacy and probably high prevalence of safety efficacy issues.
In the current study the next DRP observed in DM patients where they did not receive any medications in
spite of existence of indications 26(11.5%). In a similar study conducted by Huri HZ(8) in a tertiary care
hospital in Malaysia showed that 15(3.9%) of DRP where no drugs were prescribed though existence of
clear indication. In another similar study conducted in Hong Kong by Chung AYS et al(22) showed
35(8.4%)of DRP where DM patients did not receive any medication though there is an existence of clear
indications.
Out of 250 type 2 DM patients, out of 226 DRPs 1(0.44%) of DRP identified as patients received
inappropriate form of drugs. The form of drug the patient received was not appropriate for the patient’s
condition.in a similar study conducted by Huri HZ et al (9) in a tertiary care hospital in Malaysia showed a
similar result where only 1(0.2%) DRP was identified in DM patient receiving inappropriate form of drugs.
The number of this DRP is really less compare to others may be because the physician prescribes the correct
form of drugs to the patients in most of the time.
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It was found by examining the nursing record that some prescribed drugs were not available in the pharmacy
and number of such DRPs observed were 4(1.77%). In a similar study observed by Zazuli Z et al(7) in
Indonesia showed that in a tertiary care hospital for 2(0.7%) DRPS were prescribed drugs were not
available in the pharmacy for DM patients. The result was almost similar as ours.
In 250 type 2 DM patient, out of 226 DRPS, 3(1.32%) of DRPs were recorded as patients received drugs of
wrong strength. The doses mentioned in the order are not available in the market but they were written in the
doctor’s record. In a similar prospective study conducted by Yimama M et al (23) in a tertiary care hospital in
Ethiopia which showed that 7 (1.8%) DRPs recorded where DM patients receiving drugs of wrong strength.
The result was almost similar as ours
From the nursing record, the DRP identified was the DM in patients were given drugs at inappropriate time
or at inappropriate interval of time 2(0.88%). The time given in the medication order was different from the
time of the medication received by the patients. The doses of the drugs were skipped and were administered
at wrong time. According to a study conducted by Huri HZ et al(9) in a tertiary care hospital in Malaysia
which T2DM patients showed that 6(1.2%) DRPS of patients receiving drugs at inappropriate dosing
interval.
In the current study DM patients, 8(3.53%) DRPS were observed where patients’ drugs were not
administered at all during the stay in the hospital. These drugs were prescribed but the patient did not
receive during the stay in the hospital. Likewise, a study conducted by Subeesh VK et al (24) in a tertiary
hospital in India showed that for 38(11.2%) patients’ drugs were not administered during the stay in the
hospital. In another study conducted in a teaching hospital in India by Shareef J et al(25) et al showed that
4(2.11%)of DRPs in DM patients where they did not receive any drugs during the stay in the hospital.
In the study some patient related problems were also observed. The DRP observed was patients refused to
take the drugs 17(7.52%) Such patients were given psychological counselling during the stay in the hospital
to increase the compliance with their medications. In the study conducted by Ogbonna B et al(26) in a tertiary
care hospital in Nigeria where they recorded 104(26.1%) DRPS in type 2 DM patients where patients
preferred not to take the medications and were non-compliant.
The next DRP observed was the history of hypoglycemics not recorded for the DM in patients 52 (23%)
According to a study in Jordan by Al Azzam SI et al (27) who conducted with 2898 patients where only
392(13.52%) of DRP recorded which included patients’ medical and medication history was not taken.
Additional information should have been noted during the admission of the patients.
The greatest number of problems recorded was insufficient medical information. It was observed that
patients had insufficient clinical information during the stay in Hospital 85(37.6%). The blood sugar levels
and other necessary biochemical parameters were not monitored. In a similar study conducted by Al Azzam
SI et al(27) in a tertiary care hospital in Jordan they observed 32,348 DRPs, out of which 13,498
(41.73%)DRPs were observed as insufficient record of their clinical parameters. Additional clinical
monitoring should have been of the patients done during the stay in the hospital.
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LIMITATION
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6.LIMITATIONS
-Not all the data were available, for say social history of the patient, BMI, personal history, proper history of
the comorbidities etc
-Few biochemical investigation values were not recorded/conducted, for example-HbA1C value, Random
blood sugar, Fasting blood sugar values, HDL and LDL levels etc
-As it is a retrospective study, containing all the data is impossible, patient's perspective to the treatment is
always a question mark.
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7.CONCLUSION
Though Diabetes Mellitus is a manageable disease yet it is highly prevalent around the world. We
carried out a retrospective study in a tertiary care to assess Drug related problems in type 2 diabetic
patients. We found 226 Drug related problems in 250 selected patients with an average of 0.91 DRP
per patient. These are Potential drug-drug interaction(7.09%), insufficient clinical information
(37.6%), adverse drug reactions (4.86%), no indication of drugs (0.44%), untreated
indication(11.5%), prescribed drugs not available(1.77%), wrong dose (1.32%), inappropriate drug
form(0.44%), inappropriate dosing interval(0.88%), drugs prescribed but not administered (3.53%),
patient refused to take drugs(7.52%) and no update medication list(23%) were the problems
identified in this study. Thus, this study concludes that identifying such problems can help in
preventing the occurrence of further complications in the patients related to drugs. It thus shows
there is a need of a clinical pharmacist in the hospital to reduce the drug relate problems in the
patients.
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FUTURE DIRECTIONS
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8.FUTURE DIRECTIONS
-Conducting a prospective study in this field would yield much better outcomes with better precision.
-Combining the outcomes of both prospective and retrospective would help in providing better treatment
option and patient care.
- This retrospective study could always act as a basis to conduct any further studies in this field.
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CASE RECORD FORM (CRF)
STUDY: Drug Related Problems in Type II Diabetes Mellitus patients with comorbidities-A
Retrospective study.
DEPARTMENT OF PHARMACY PRACTICE, KASTURBA HOSPITAL, MANIPAL
HOSP. NO:

DATE OF ADMISSION:
DATE OF DISCHARGE:

AGE:

WEIGHT:

SEX: M/F:

COMPLAINTS ON ADMISSION:

MEDICAL HISTORY:
1. Age at diagnosis of DM type II:
2. Other history:
MEDICATION HISTORY:
1. For Diabetes Mellitus:
2. For Other morbidities:
SOCIAL HISTORY:
FAMILY HISTORY:
1. Mother suffers from DM Type II:
2. Father suffers from DM Type II:
3. No. of relative with DM Type II:

YES
YES

NO
NO

UNKNOWN
UNKNOWN

PREVIOUS ALLERGIES:
DEMOGRAPHY OF THE PATIENT
Characteristics
1.

Number of drugs received:

2.

Length of hospital stay:

3. Number of comorbidities
ROUTINE BIOCHEMICAL INVESTIGATIONS
Urea:
FBS:
PPBS:
S.Cr :
RBS:
Na:
HbA1C:
K:

HDL:
LDL:
TGs:
TC:
Hb:

Alb:
Glob:
AST:
ALT:
ALP:
T.Bili
D.Bili:

BP:
Pulse:

COMORBIDITIES:

DM COMPLICATIONS
1.
2.
3.
4.
5.
6.

Hypertension:
YES
NO
Dyslipidemia:
YES
NO
Congestive heart failure YES
NO
IHD
YES
NO
Angina pectoris
YES
NO
Others
YES
NO

FINAL DIAGNOSIS:

1.
2.
3.
4.

Retinopathy:
Neuropathy:
Nephropathy:
Diabetic foot
Ulcers:

YES
YES
YES

NO
NO
NO

YES

NO

DRUG TREATMENT CHART:
DRUG WITH DOSE & ROUTE
1
BRAND
NAME

GENERIC
NAME

ROA

FREQ

2

3

4

5

6

7

8

9

10

DOSE

Discharge medications
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Appendix III

SL NO.

DRUG RELATED PROBLEMS

1.

Drug use without indication

2.

Improper drug selection

3.

Sub therapeutic dose

4.

Drug interaction

5.

Overdose

6.

Adverse drug reaction

7.

Untreated indication

8.

Failure to receive drugs

9.

Others

Yes/No

TOTAL
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Appendix-IV

PRIMARY DOMAIN
1. Drug selection

Code V9.0
C1.1
C1.2
C1.3
C1.4
C1.5
C1.6

2. Drug form
3. Dose selection

4. Treatment duration
5. Dispensing

6. Drug use process

7. Patient related

8. Patient transfer related

C1.7
C2.1
C3.1
C3.2
C3.3
C3.4
C3.5
C4.1
C4.2
C5.1
C5.2
C5.3
C5.4
C6.1
C6.2
C6.3
C6.4
C6.5
C6.6
C7.1
C7.2
C7.3
C7.4
C7.5
C7.6
C7.7
C7.8
C7.9
C7.10
C8.1
C8.2
C8.3
C8.4
C8.5

9. Other

C9.1
C9.2
C9.3

CAUSE
Inappropriate drug according to guidelines/formulary
Inappropriate drug (within guidelines but otherwise
contra-indicated)
No indication for drug
Inappropriate combination of drugs, or drugs and herbal
medications, or drugs and dietary supplements
Inappropriate duplication of therapeutic group or active
ingredient
No or incomplete drug treatment in spite of existing
indication
Too many drugs prescribed for indication
Inappropriate drug form (for this patient)
Drug dose too low
Drug dose too high
Dosage regimen not frequent enough
Dosage regimen too frequent
Dose timing instructions wrong, unclear or missing
Duration of treatment too short
Duration of treatment too long
Prescribed drug not available
Necessary information not provided
Wrong drug, strength or dosage advised (OTC)
Wrong drug or strength dispensed
Inappropriate timing of administration or dosing intervals
Drug under-administered
Drug over-administered
Drug not administered at all
Wrong drug administered
Drug administered via wrong route
Patient uses/takes less drug than prescribed or does not
take the drug at all
Patient uses/takes more drug than prescribed
Patient abuses drug (unregulated overuse)
Patient uses unnecessary drug
Patient takes food that interacts
Patient stores drug inappropriately
Inappropriate timing or dosing intervals
Patient administers/uses the drug in a wrong way
Patient unable to use drug/form as directed
Patient unable to understand instructions properly
No medication reconciliation at patient transfer.
No updated medication list available.
Discharge/transfer information about medication
incomplete or missing
Insufficient clinical information about the patient.
Patient has not received necessary medication at discharge
from hospital or clinic.
No or inappropriate outcome monitoring (incl. TDM)
Other cause; specify
No obvious cause
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